

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/774,681	02/08/2004	Michael Scott Ehrlich	C1159.70000US01	9429
7590 05/02/2007 Patrick R.H. Waller, Ph.D. Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, MA 02210			EXAMINER	
			CLOW, LORI A	
			ART UNIT	PAPER NUMBER
•			1631	
		4		
			MAIL DATE	DELIVERY MODE
	•		05/02/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06)

Paper No(s)/Mail Date

6) Other: \_

#### **DETAILED ACTION**

Applicant's election without traverse of Group II, claims 19 and 25-36 in the reply filed on 5 March 2007 is acknowledged. Claims 6-18 and 20-24 are cancelled. Claims 1-5, 26, 37 and 38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 5 March 2007.

Claims 19, 25, and 27-36 are examined herein.

### **Priority**

Priority to US Provisional Application 60/527,205, filed 4 December 2003 is acknowledged.

### **Drawings**

The drawings filed 8 February 2004 are accepted.

# Claim Rejections - 35 USC § 112-2<sup>nd</sup> paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 19, 25, and 27-36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 19 recites, "determining a cell distribution profile for a plurality of the intact cells using a procedure that sorts the intact cells based on an amount of a physiological variable in each of the sorted cells". It is unclear what distribution is being measured. Is it a distribution of different cell types in a sample or a distribution of cells with a certain cellular marker. The claimed method step is directed to obtaining a profile, however, the parameters of the profile are unclear. Clarification is requested.

Claim 25 recites, "a method of recovering the blood glucose level history of a patient". It is unclear what is intended by "recovering". Has the blood glucose level in the method been previously lost? Clarification is requested.

Claim 25 recites, "obtaining a cell distribution profile by sorting a plurality of the intact cells based on the amount of glycated hemoglobin...and determining the patient's glucose level history based on the cell distribution profile". It is unclear as to what about the cell distribution profile will determine a patient's blood glucose history. Further, what distribution is being evaluated? The ratio of non-glycated to glycated red blood cells, for example? Clarification is requested.

Claim 26 recites, "wherein the patient's blood glucose level history is obtained by comparing the patient's cell distribution profile to one or more reference profiles". It is unclear as to what encompasses a "reference profile". Is it a reference profile of blood glucose levels or some other reference profile? Clarification is requested.

Claim 27 recites, "wherein the patient's blood glucose level history is obtained using an algorithm". It is unclear for what the algorithm is used to obtain a glucose history. Is the algorithm for assessing glycation events or some other purpose? Clarification is requested.

Claim 33 recites, "the method of claim 25 comprising the additional step of determining whether the patient has Type I, Type II, or gestational diabetes". It is unclear what parameters are to be considered in order to determine whether a patient has Type I, Type II, or gestational diabetes? If the distribution is within a certain range, for instance, does that indicate diabetes? Clarification is requested.

Claim 34 recites, "the additional step of determining a treatment regime for the patient". It is unclear what the parameters of a treatment regime are based. Clarification is requested.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 1. Claim 19 is rejected under 35 U.S.C. 102(e) as being anticipated by US 6,540,895 (Spence et al.).

The instant claims are drawn to a method of obtaining a cell distribution profile of a patient comprising obtaining a biological sample and determining a cell distribution based upon a physiological variable of the sorted cells.

6,540,895 ('895) teaches a device and method for sorting cells based upon a desired characteristic (abstract). For example, labeled cells are sorted depending on the level of reporter

in the cells. The method is useful for sorting blood cells and can be used to sort any cell on the basis of whether or not it expresses a detectable protein (column 4, line 54-64).

2. Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by 6,784,981 (Roche et al.).

6,784,981 ('981) teaches flow cytometric methods and systems for analysis of biological samples, particularly blood sample (abstract). The system can determine a distribution of white blood cells and other cells in a whole blood sample. The system is capable measuring hemoglobin in the sample (physiological variable) (column 30).

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 25 and 27-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over 6,540,895 (Spence et al.) in view of 4,835,097 (Saunders).

6,540,895 ('895) teaches a device and method for sorting cells based upon a desired characteristic (abstract). For example, labeled cells are sorted depending on the level of reporter in the cells. The method is useful for sorting blood cells and can be used to sort any cell on the basis of whether or not it expresses a detectable protein (column 4, line 54-64).

'895 does not teach the method as applied to diabetes using glycated hemoglobin.

However, '097 teaches the measurement of glycolated hemoglobin for assessing the physical condition of a diabetic patient over time (column 1). Further, '097 teaches the monitoring of glucose using the hemoglobin levels over time (column 4). While '097 does not specifically teach an algorithm to obtain a blood glucose level, '097 does teach incremental interval evaluation (column 9). It would have been prima facie obvious to one of skill in the art at the time of the invention to have assessed levels using an algorithm to generate intervals for assessment of patient glucose. One would have been motivated to do so because glucose history facilitation using a computer is taught at column 11.

It would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to have used the cell sorter of '895 in the diabetes assessment of '097. One would have been motivated to do so because '895 teaches that the cell sorter can be used to sort cells for any characteristic, in particular it is most useful to separate blood cells (column 4).

No claims are allowed.

## **Inquiries**

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The Central Fax Center Number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lori A. Clow, Ph.D., whose telephone number is (571) 272-0715. The examiner can normally be reached on Monday-Friday from 10 am to 6:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

April 29, 2007

Lori A. Clow, Ph.D.

Art Unit 1631

Suit Clan Patent Examene